Diabetic Patients' Perspective About New Technologies Used in Managing Diabetes Mellitus in Saudi Arabia: A Cross-Sectional Study

Omar M. Al-Nozha, Esraa K. Alshareef, Afnan F. Aljawi, Enas T. Alhabib, Raghad S. AlMahweeti, Sarah A. Aljuhani, Sawsan A. Alamri, Ohoud S. Alahmadi

Abstract

Background: Diabetes technologies are hardware, devices, and software that are used by people with diabetes to manage their condition, from lifestyle interventions to the monitoring of blood glucose levels. The development of these technologies is advancing, but their use in Saudi Arabia is under-researched.

Objectives: To appraise the awareness of using new technological options in managing patients with diabetes and to assess the patients’ satisfaction while using them.

Method: This was an e-questionnaire-based cross-sectional study. The targeted population of the study was patients with diabetes in Saudi Arabia. A total of 452 respondents participated in a survey in the period between 2020 and 2021. The collected data were analyzed using descriptive statistical methods and Chi-squared tests.

Results: Some 69% of participants were aware of the new technologies used in managing diabetes. There were discrepancies between the awareness and the use of new technologies. Several causes of non-use were identified; the main cause was high cost, as reported by more than half of non-users (53.2%). Other causes included non-availability and difficulty of use. Mobile health applications had the highest use rate (13.5%) among new technologies; patients reported using them mostly for blood glucose monitoring, physical activity, and nutritional programs. Patients’ satisfaction was higher for modern technologies than for conventional methods.

Conclusion: The results indicate that awareness of the new technologies used in managing diabetes was higher than their use. Moreover, the use of modern technologies improved the satisfaction of patients.

Categories: Endocrinology/Diabetes/Metabolism, Healthcare Technology
Keywords: diabetes mellitus, satisfaction, awareness, management, new technologies

Introduction

Diabetes mellitus (DM) is one of the most common chronic diseases; around 537 million people aged 20-79 years were suffering from it at the end of 2021, and it is estimated that by 2030 the number will increase to be 643 million adults worldwide [1]. Recently the International Diabetes Federation (IDF) has reported the prevalence of DM in the Kingdom of Saudi Arabia (KSA) to be 18.3% among adults [1].

Diabetes technology is defined as "hardware, devices, and software that patients with diabetes use to manage their condition, from lifestyle to blood glucose levels" [2]. Recently, it has been divided into two main categories: insulin administered devices, starting from a simple insulin pen to advanced insulin pumps, and blood glucose monitoring devices which range from simple glucose meters to continuous glucose monitoring (CGM) devices [2]. Many studies have shown the efficacy of new technologies and an overall improvement in diabetes control and patient satisfaction. For CGM, hemoglobin A1c (HbA1c) reduction was shown in multiple studies [2-5] in both type 1 and type 2 DM and reductions in hypoglycemia specifically for type 1 patients. Insulin pumps were shown to reduce HbA1c and the frequency of hypoglycemia and hyperglycemia levels, especially when combined with sensors, and increased patients’ treatment satisfaction [2, 6]. A novel interstitial device known as flash glucose monitoring (FGM) which was used to obtain glucose levels instantly has been associated with improvements in HbA1c levels and reductions in hypoglycemia; it was also found to improve user satisfaction [7]. Another novel way to engage patients in their DM management is mobile health (‘mHealth’) which is a term describing digital health, defined by the WHO as "medical and public health practice supported by mobile devices" that are intended to improve health outcomes and quality of life by nutrition and exercise advice, encouraging glucose monitoring, the interpretation of results, adjusting medication doses, and decreasing complications [8]. Although health applications have been developing rapidly to help people manage their diabetes, the evidence of their
effectiveness and safety for diabetes remains limited and requires evaluation of the accuracy, clinical validity, and quality [8].

Diabetes is a lifelong disease that requires continuous self-management in order to decrease the probability of long-term complications and prevent acute deterioration of the condition [9]. Better self-management leads to improvements in patients’ conditions, especially HbA1c, which is associated with a lower incidence of complications and a decrease in mortality rate among patients with diabetes [9]. Good education, using new technology, and follow-up can show significant improvements in the quality of life for people with diabetes [2].

Although these technologies are developing rapidly, the impact of their use in Saudi Arabia is still not clear. In our study, we aimed to explore patients’ perspectives, awareness, and satisfaction regarding these new technologies.

Materials And Methods

Subjects
We used an e-questionnaire-based cross-sectional study in the period between 2020 and 2021, after obtaining the approval of the ethical and research committee of Taibah University, Madinah, Saudi Arabia. An electronic informed consent of each participant was obtained. The study has followed Helsinki Declaration in all stages. The target population was people with diabetes in the KSA. A sample size of 385 participants was calculated using the surveymonkey.com with a 5% margin of error and 95% confidence level. The actual sample size was 452 which was increased for better representation of the population. Patients with type 1, type 2, or gestational diabetes, aged between 18 and 60 years, who could read Arabic clearly and could use social media websites and applications, were included. There were no excluding criteria.

Data collection and research tool
The e-questionnaire was designed based on the literature review of new technologies used in diabetes management. It was distributed on social media websites with an electronic message to explain the purpose of our study. The questionnaire was divided into sections: the first part consisted of seven questions about demographic data, the second part consisted of health information, i.e., type of diabetes and HbA1c level, and then directed the participants to the following part of the questionnaire according to their answers. The last sections showed the different technologies and consisted of questions about patient awareness of these technologies (Appendix 1). The satisfaction section was inspired by a questionnaire used to assess treatment satisfaction of another study, with some changes to the items to adapt to the new technologies that we measured and the Likert scale was used to assess patient responses [10]. (see Table in Appendix 1).

The validity and reliability of the questionnaire were tested through a pilot study. The questionnaire was given in a face-to-face manner by the researchers to 38 patients with diabetes chosen randomly in an endocrine clinic. The pilot study sample was not included in the current study. Also, the questionnaire was reviewed by two health experts to explore whether any incomprehensible items led to misunderstandings. One of the problems we faced was that the patients could not differentiate between some of the technologies, so we added a brief explanation of each technology. Also, a section on glucometers was added. After the questionnaire reached its current final form, the poll was opened for two weeks and the data was collected automatically.

All questionnaire items were translated into the Arabic language by a healthcare physician and a translator expert fluent in both Arabic and English languages. The resulting Arabic questionnaire was then translated back into the English language by another two experts fluent in both languages. Those two experts were blinded to the questionnaire’s original English version. The back-translated version of the questionnaire was compared with the original English one to check the translation quality which is the back-translation method recommended by the World Health Organization (WHO) [11].

Data analysis
The statistical analysis was done using Statistical Package for Social Sciences (SPSS) software, version 22.0, for Windows (SPSS, Inc., Chicago, IL). The demographic- and diabetes-related data of the 452 patients with diabetes studied were tabulated and presented in frequency number, percentage, mean, and standard deviation. The awareness of the patients of the new technologies in managing diabetes was calculated. The frequency of use of different new health technologies among the studied patients was tabulated. Satisfaction was calculated and compared among the studied patients by the type of technology used using the Chi-square test. Chi-square Fischer exact tests were used as appropriate to compare the awareness and use of new technologies among the studied patients by their studied demographic- and diabetes-related factors. The p-value of <0.05 was considered as the cut-off value for significance. The odds ratio (OR) for the association of the use of new technologies with the studied demographic- and diabetes-related factors were also calculated.
Results
A total of 452 patients with diabetes from KSA were included in the study analyses. The characteristics of the studied patients are shown in Table 1. The mean age of the participants was 38.2 ± 12.4 years and 45.15% of them were >40 years. About two-thirds of the studied patients were female (66.8%) and the majority were Saudi citizens (91.4%). The educational level of the studied patients was 69.9% university and higher, 21% secondary education, and 9.1% less than secondary education level. Half of the studied patients were employees (49.6%), and 53.1% reported a monthly income of less than 10,000 SR. Of the studied patients, type 1 diabetes was found in 36.9% and type 2 in 38.8%. Diabetes duration of more than 10 years was found in 160 patients, representing 35.4% of the studied sample. HbA1c level was found to be >7.5% in about half of the studied patients with diabetes (48.5%).
| Characteristics                        | n=452  |
|---------------------------------------|--------|
| Age in years; mean ± SD (range)       | 38.2 ± 12.4 (18-60) |
| Age in years                         |        |
| ≤ 40                                  | 248 (54.9) |
| > 40                                  | 204 (45.1) |
| Sex                                   |        |
| Male                                  | 150 (33.2) |
| Female                                | 302 (66.8) |
| Nationality                           |        |
| Saudi                                 | 413 (91.4) |
| Non-Saudi                             | 39 (8.6) |
| Less than secondary                   | 41 (9.1) |
| Educational level                     |        |
| Secondary                             | 95 (21.0) |
| University and higher                 | 316 (69.9) |
| Job                                   |        |
| Student                               | 80 (17.7) |
| Employee                              | 224 (49.6) |
| Not employee                          | 148 (32.7) |
| Income                                |        |
| < 10000 Saudi Riyal                   | 240 (53.1) |
| 10-20000 Saudi Riyal                  | 176 (38.9) |
| > 20000 Saudi Riyal                   | 236 (8.0) |
| Type of diabetes                      |        |
| Don't know                            | 167 (36.9) |
| Type1                                 | 130 (38.8) |
| Type2                                 | 25 (5.5) |
| Gestational                           | 130 (28.8) |
| Duration of diabetes in years         |        |
| < 1                                   | 88 (19.5) |
| 1-5                                   | 125 (27.7) |
| 6-10                                  | 79 (17.5) |
| > 10                                  | 160 (35.4) |
| Hemoglobin A1c level                  |        |
| Don't know                            | 128 (28.3) |
| < 6.5                                 | 56 (12.5) |
| 6.5-7.5                               | 105 (23.2) |
| > 7.5                                 | 163 (36.1) |

**TABLE 1: Characteristics of the studied patients with diabetes (n=452).**

Data are presented by the mean ± SD or by n (%).

SD, standard deviation

Regarding the awareness of new technologies, we found that the majority of participants were aware of it: 312 patients out of the 452 studied patients (69%). The remaining 140 patients (31%) were not aware. The prevalence rates of the use of new technologies in this present study for mobile health applications, flash monitoring, blood glucose monitoring, and insulin pumps among the studied patients with diabetes were 15.3%, 12.2%, 11.3%, and 4%, respectively. Among the studied subjects, 355 reported the use of a glucometer (78.5%). With exception of glucometer use, there were great discrepancies between the awareness by the studied patients of the new technologies and their actual use (Figure 1).
The main cause of not using technologies was their high cost, reported by 53.2% of the respondents (n = 231). Non-availability of a technology and difficulty in its understanding and use was reported by 20.3% and 21.2%, respectively. Lack of advice by treating doctors and fear or lack of trust was reported by 3% and 2.2% of respondents, respectively. Furthermore, the main sources of knowledge were doctors, friends, and social media. Television (TV) played a minor role as a source of knowledge, while newspapers appeared to have no role in acquiring knowledge about new technology in managing diabetes.

For mobile health applications, the most commonly used function among the studied subjects (n = 61) was blood glucose monitoring (93.4%) followed by physical activity programs (44.3%) and nutritional programs (39.3%). Finally, the use of mobile health applications for insulin level determination was reported by only 3.3% of the studied subjects.

Table 2 shows the awareness of the studied patients about new technologies by their characteristics. Significant higher rates of awareness were found among patients aged ≤ 40 years (83.4%) and among students (78.7%). Although not significant, the awareness was also high among male patients (72%), secondary and highly educated patients, and those who reported high monthly family income with an awareness rate of 74.7%, 69.5%, and 80.6%, respectively. For the studied diabetes factors, the rate of awareness was significantly higher among patients with type 1 diabetes (80.8%), and among those patients with HbA1c < 6.5 (80.4%), and HbA1c between 6.5 and 7.5 (83.8%). Although not significant, the rate of awareness was higher among patients with diabetes duration between 6 and 10 years (74.7%).
TABLE 2: Awareness of the studied patients about new technologies by their characteristics (n=452).

*A p-value less than 0.05 is considered statistically significant

| Characteristics       | Subgroups                  | Aware (n=312) | Not aware (n=140) | p-value* |
|-----------------------|----------------------------|---------------|-------------------|----------|
| Age in years          | ≤ 40                       | 182 (63.7)    | 66 (36.3)         | 0.001    |
|                       | > 40                       | 130 (63.7)    | 74 (36.3)         |          |
| Sex                   | Male                       | 108 (72.0)    | 42 (28.0)         | 0.35     |
|                       | Female                     | 204 (67.5)    | 98 (32.5)         |          |
| Educational level     | Less than secondary        | 22 (53.7)     | 19 (46.3)         | 0.10     |
|                       | Secondary                  | 61 (74.7)     | 24 (25.3)         |          |
|                       | University and higher      | 219 (69.3)    | 97 (30.7)         |          |
| Job                   | Student                    | 63 (78.7)     | 17 (21.3)         |          |
|                       | Employee                   | 147 (65.6)    | 77 (34.4)         | 0.02     |
|                       | Not employee               | 101 (68.2)    | 47 (31.8)         |          |
| Income                | < 10000 Saudi Riyal        | 165 (68.7)    | 75 (31.3)         | 0.26     |
|                       | 10-20000 Saudi Riyal       | 118 (67.0)    | 58 (33.0)         |          |
|                       | > 20000 Saudi Riyal        | 29 (80.6)     | 7 (19.4)          |          |
| Type of diabetes      | Don't know                 | 73 (56.2)     | 57 (43.8)         |          |
|                       | Type1                      | 135 (60.8)    | 32 (39.2)         |          |
|                       | Type2                      | 85 (65.4)     | 45 (34.6)         |          |
|                       | Gestational                | 19 (76.0)     | 6 (24.0)          |          |
|                       | < 1                        | 47 (53.4)     | 41 (46.6)         |          |
| Duration of diabetes  | 1-5                        | 91 (72.8)     | 34 (27.2)         | 0.11     |
|                       | 6-10                       | 59 (74.7)     | 20 (25.3)         |          |
|                       | > 10                       | 115 (71.9)    | 45 (28.1)         |          |
|                       | Don't know                 | 63 (49.2)     | 65 (50.8)         |          |
| Hemoglobin A1c level  | < 6.5                      | 45 (80.4)     | 11 (19.6)         | 0.0001   |
|                       | 6.5-7.5                    | 88 (83.8)     | 17 (16.2)         |          |
|                       | > 7.5                      | 116 (71.2)    | 47 (28.8)         |          |

Table 3 presents the satisfaction with the use of different new technologies among the studied patients with diabetes. There were statistically significant differences for all studied satisfaction items according to the type of technology used. Higher rates of satisfaction for all studied items were related to those patients reporting the use of mobile health applications, FGM, and continuous glucose monitoring; the lowest rate was among those patients using a glucometer. Those using an insulin pump reported a high rate of satisfaction for only the first studied satisfaction items.
| Satisfaction items                                      | Agree n (%) | CGM (n=51) | FGM (n=55) | Insulin pump (n=18) | Mobile health applications (n=61) | p-value * |
|--------------------------------------------------------|-------------|------------|------------|---------------------|-----------------------------------|-----------|
| I feel generally fine with my diabetes treatment       | 40 (11.3)   | 43 (84.3)  | 48 (87.3)  | 13 (72.2)           | 57 (93.4)                         | 0.0001    |
| Easy and comfortable treatment method                  | 39 (10.9)   | 42 (82.3)  | 49 (89.1)  | 12 (66.7)           | 54 (88.5)                         | 0.0001    |
| I feel confident dealing with my diabetes              | 38 (10.5)   | 40 (78.4)  | 46 (83.6)  | 12 (66.7)           | 54 (88.5)                         | 0.0001    |
| I am not worried about low blood sugar                 | 28 (7.9)    | 29 (56.9)  | 32 (58.1)  | 7 (38.9)            | 43 (70.5)                         | 0.0001    |
| I am not worried about high blood sugar                | 25 (7.0)    | 26 (50.9)  | 29 (52.7)  | 8 (44.4)            | 40 (65.6)                         | 0.0001    |

**TABLE 3: Satisfaction of the use of different new technologies among the studied patients with diabetes.**

CGM, continuous glucose monitoring; FGM, flash glucose monitoring

*A p-value less than 0.05 is considered statistically significant.

Table 4 shows the use of CGM and FGM among the studied patients with diabetes according to their demographic- and diabetes-related factors. Statistically significant differences were detected among the studied patients according to all studied demographic factors, with the exception of income, for both techniques. For CGM, a higher rate of use was found among patients aged ≤40 years (16.1%), female patients (11.9%), highly educated patients (13.3%), and students (22.5%). For the studied diabetes factors, a higher rate of use was found among patients with type 1 diabetes (23.4%), with an OR of 6.3 for those patients. Also, the use was higher among patients with a duration of diabetes of more than 10 years (15%). Significantly increased use of CGM was also found among patients with HbA1c level <6.5 (17.9%) and among those with HbA1c levels between 6.5 and 7.5 13 (18.1%). For FGM, the higher rate of use was among patients aged ≤40 years (18.5%), highly educated patients (15.2%), and students (26.3%). A significantly higher rate of use was found among patients with type 1 diabetes (28.1%) and among those with HbA1c level between 6.5 and 7.5 (21%), with a higher probability of use as indicated by the calculated ORs.
| Characteristics          | CGM Use (n=51) | CGM Not use (n=401) | OR       | P-value * | FGM Use (n=55) | FGM Not use (n=397) | OR       | P-value * |
|--------------------------|----------------|---------------------|----------|-----------|----------------|---------------------|----------|-----------|
| Age in years             |                |                     |          |           |                |                     |          |           |
| ≤ 40                     | 40 (16.1)      | 208 (83.9)          | 1.00     | 0.0001    | 46 (18.5)      | 102 (81.5)          | 1.00     | 0.0001    |
| > 40                     | 11 (5.4)       | 193 (94.6)          | 0.30     |           | 9 (4.4)        | 195 (95.6)          | 0.10     |           |
| Sex                      |                |                     |          |           |                |                     |          |           |
| Male                     | 15 (10.0)      | 135 (90.0)          | 1.00     | 0.002     | 17 (11.3)      | 133 (88.7)          | 1.00     | 0.01      |
| Female                   | 36 (11.9)      | 266 (88.1)          | 1.20     |           | 38 (12.6)      | 264 (87.4)          | 1.15     |           |
| Less than secondary      | 1 (2.4)        | 40 (97.6)           | 1.00     |           | 0 (0.0)        | 41 (100.0)          | 1.00     |           |
| Educational level        |                |                     |          |           |                |                     |          |           |
| Secondary                | 8 (8.4)        | 87 (91.6)           | 3.70     | 0.04      | 7 (7.4)        | 88 (92.6)           | -        | 0.01      |
| University and higher    | 42 (13.3)      | 274 (86.7)          | 6.10     |           | 48 (15.2)      | 268 (84.8)          | -        |           |
| Job                      |                |                     |          |           |                |                     |          |           |
| Student                  | 18 (22.5)      | 62 (77.5)           | 100     |           | 21 (26.3)      | 59 (73.7)           | 1.00     |           |
| Employee                 | 19 (8.5)       | 205 (91.5)          | 0.30     | 0.02      | 14 (6.3)       | 210 (93.7)          | 0.20     | 0.0001    |
| Not employee             | 14 (9.5)       | 134 (90.5)          | 0.36     |           | 20 (13.5)      | 128 (86.5)          | 0.45     |           |
| Income                   |                |                     |          |           |                |                     |          |           |
| < 10000 Saudi Riyal      | 26 (10.8)      | 214 (89.2)          | 1.00     |           | 29 (12.1)      | 211 (87.9)          | 1.00     |           |
| 10-20000 Saudi Riyal     | 18 (10.2)      | 158 (89.8)          | 0.95     | 0.12      | 18 (10.2)      | 158 (89.8)          | 0.83     | 0.09      |
| > 20000 Saudi Riyal      | 7 (19.4)       | 29 (80.6)           | 2.00     |           | 8 (22.2)       | 28 (77.8)           | 2.10     |           |
| Type of diabetes         |                |                     |          |           |                |                     |          |           |
| Don't know               | 6 (4.6)        | 124 (95.4)          | 1.00     |           | 3 (2.3)        | 127 (97.7)          | 1.00     |           |
| Type1                    | 39 (23.4)      | 128 (76.6)          | 6.30     | 0.0001    | 47 (28.1)      | 120 (71.9)          | 16.5     |           |
| Type2                    | 5 (3.8)        | 125 (96.2)          | 0.95     |           | 3 (2.3)        | 127 (97.7)          | 1.00     |           |
| Gestational              | 1 (4.0)        | 24 (96.0)           | 0.85     |           | 2 (8.0)        | 23 (92.0)           | 3.70     |           |
| Duration of diabetes in years |                |                     |          |           |                |                     |          |           |
| < 1                      | 5 (5.7)        | 83 (94.3)           | 1.00     |           | 5 (5.7)        | 83 (94.3)           | 1.00     |           |
| 1-5                      | 14 (11.2)      | 111 (88.8)          | 2.10     | 0.16      | 14 (11.2)      | 111 (88.8)          | 2.10     | 0.12      |
| 6-10                     | 8 (10.1)       | 71 (89.9)           | 1.90     |           | 12 (15.2)      | 67 (84.8)           | 3.00     |           |
| > 10                     | 24 (15.0)      | 136 (85.0)          | 2.90     |           | 24 (15.0)      | 136 (85.0)          | 2.90     |           |
| Hemoglobin A1c level     |                |                     |          |           |                |                     |          |           |
| Don't know               | 3 (2.3)        | 125 (97.7)          | 1.00     |           | 3 (2.3)        | 125 (97.7)          | 1.00     |           |
| < 6.5                    | 10 (17.9)      | 46 (82.1)           | 9.00     | 0.0001    | 8 (14.3)       | 48 (85.7)           | 6.90     |           |
| 6.5-7.5                  | 19 (18.1)      | 86 (81.9)           | 9.20     |           | 22 (21.0)      | 83 (79.0)           | 11.0     |           |
| > 7.5                    | 19 (11.6)      | 144 (88.4)          | 5.50     |           | 22 (13.5)      | 141 (86.5)          | 6.50     |           |

**TABLE 4:** Use of CGM and FGM among the studied patients by their demographic- and diabetes-related factors.

*A p-value less than 0.05 is considered statistically significant*

CGM, continuous glucose monitoring; FGM, flash glucose monitoring; OR, odds ratio

Table 5 shows the use of insulin pumps and mobile health applications among the studied patients with diabetes by their demographic- and diabetes-related factors. Except for age, the use of insulin pumps did
not show statistically significant differences in the studied demographic factors. However, a higher rate of use of insulin pumps was found among patients aged ≤40 years (6.5%), males (5.3%) 14 and students (8.8%), and among those with high income (8.3%). For the studied diabetes factors, a significantly higher rate of insulin pump usage was found among patients with type 1 diabetes (10.2%), duration of diabetes of more than 10 years (8.1%), and among those patients with HbA1c levels between 6.5 and 7.5 (9.5%). A significantly higher rate of use of mobile health applications was found among patients aged ≤40 years (21%) and among students (26.3%). Although not significant, the use of mobile health applications was also higher among male patients (17.3%), highly educated patients (15.2%), and among those patients reporting high-income levels (19.4%). For the studied diabetes factors, a significantly higher rate of mobile health application usage was found among patients with type 1 diabetes (28.1%), and 19.6% and 20% among those patients with HbA1c levels of <6.5 and between 6.5 and 7.5, respectively.
| Characteristics | Insulin pump | Mobile health applications |
|-----------------|--------------|---------------------------|
| Device name     | Use (n=18)   | Not in use (n=434) | OR | P-value* | Use (n=61) | Not in use (n=391) | OR | P-value* |
| Age in years    |              |                          |    |          |              |                          |    |          |
| ≤ 40            | 16 (6.5)     | 232 (93.5)               | 1.00 | 0.0001   | 52 (21.0)   | 196 (79.0)               | 1.00 | 0.0001   |
| > 40            | 2 (1.0)      | 203 (99.0)               | 0.15 |          | 9 (4.4)     | 195 (95.6)               | 0.17 |          |
| Sex             |              |                          |    |          |              |                          |    |          |
| Male            | 8 (5.3)      | 142 (94.7)               | 1.00 | 0.14     | 26 (17.3)   | 124 (82.7)               | 1.00 | 0.15     |
| Female          | 10 (3.3)     | 292 (96.7)               | 0.60 |          | 35 (11.6)   | 267 (88.4)               | 0.60 |          |
| Less than secondary | 0 (0.0) | 41 (100.0)               | 1.00 |          | 0 (0.0)     | 41 (100.0)               | 1.00 |          |
| Educational level |            |                          |    |          |              |                          |    |          |
| Secondary       | 3 (3.2)      | 92 (96.8)                | -   | 0.09     | 13 (13.7)   | 82 (82.3)                | -   | 0.12     |
| University and higher | 15 (4.7) | 301 (95.3)               | -   |          | 48 (15.2)   | 268 (84.8)               | -   |          |
| Job             |              |                          |    |          |              |                          |    |          |
| Student         | 7 (8.8)      | 73 (91.2)                | 1.00 |          | 21 (26.3)   | 59 (73.7)                | 1.00 |          |
| Employee        | 6 (2.7)      | 218 (97.3)               | 0.30 | 0.06     | 22 (9.8)    | 202 (90.2)               | 0.30 | 0.0001   |
| Not employee    | 5 (3.4)      | 143 (96.6)               | 0.35 |          | 18 (12.2)   | 130 (87.8)               | 0.40 |          |
| Income          |              |                          |    |          |              |                          |    |          |
| < 10000 Saudi Riyal | 11 (4.6) | 229 (95.4)               | 1.00 |          | 32 (13.3)   | 208 (86.7)               | 1.00 |          |
| 10-20000 Saudi Riyal | 4 (2.3) | 172 (97.7)               | 0.48 | 0.09     | 22 (12.5)   | 154 (87.5)               | 0.95 | 0.27     |
| > 20000 Saudi Riyal | 3 (8.3) | 33 (91.7)                | 1.90 |          | 7 (19.4)    | 29 (80.6)                | 1.60 |          |
| Type of diabetes |              |                          |    |          |              |                          |    |          |
| Don’t know      | 0 (0.0)      | 130 (100.0)              | 1.00 |          | 2 (1.5)     | 128 (98.5)               | 1.00 |          |
| Type1           | 17 (10.2)    | 150 (89.8)               | -   |          | 47 (28.1)   | 120 (71.9)               | 25.0 |          |
| Type2           | 1 (0.8)      | 129 (99.2)               | -   |          | 12 (9.2)    | 118 (90.8)               | 6.50 |          |
| Gestational     | 0 (0.0)      | 25 (100.0)               | -   |          | 0 (0.0)     | 25 (100.0)               | -   |          |
| Duration of diabetes in years |          |                          |    |          |              |                          |    |          |
| < 1             | 0 (0.0)      | 88 (100.0)               | 1.00 |          | 7 (8.0)     | 81 (92.0)                | 1.00 |          |
| 1-5             | 1 (0.8)      | 124 (99.2)               | -   |          | 18 (14.4)   | 107 (85.6)               | 1.95 |          |
| 6-10            | 4 (5.1)      | 75 (94.9)                | -   |          | 12 (15.2)   | 67 (84.8)                | 2.10 |          |
| > 10            | 13 (8.1)     | 147 (91.9)               | -   |          | 24 (15.0)   | 136 (85.0)               | 2.05 |          |
| Hemoglobin A1c level |        |                          |    |          |              |                          |    |          |
| < 6.5           | 2 (3.6)      | 54 (96.4)                | 4.70 |          | 11 (19.6)   | 45 (80.4)                | 31.0 |          |
| 6.5-7.5         | 10 (9.5)     | 95 (90.5)                | 13.4 |          | 21 (20.0)   | 84 (80.0)                | 32.0 |          |
| > 7.5           | 5 (3.2)      | 158 (96.8)               | 4.00 |          | 28 (17.2)   | 135 (82.8)               | 26.0 |          |

TABLE 5: Use of insulin pump and mobile health applications among the studied patients by their demographic- and diabetes-related factors.

*A p-value less than 0.05 is considered statistically significant

OR, odds ratio

Discussion
Technologies used in managing diabetes have advanced in recent years with the introduction of different types of devices. In this cross-sectional study, we aimed to measure the awareness of the modern technologies used in managing diabetes among patients with diabetes in Saudi Arabia and their satisfaction while using them; we found that out of 452 patients with diabetes, 312 (69%) of the sample were aware of these technologies. There was a significantly higher rate of awareness among patients aged <40 years (85.4%) and among students (78.7%). For the studied diabetes factors, the rate of awareness was significantly higher among patients with type 1 diabetes (80.8%), and among those patients with HbA1c of <6.5 (80.4%), and HbA1c between 6.5 and 7.5 (85.8%). So, younger patients with better control showed better awareness, but it could be the other way that the younger patients who showed better awareness had better control as a result.

The prevalence of the use of modern technology among the studied patients with diabetes was higher for mobile health applications (13.5%) followed by FGM (12.2%) and CGM (11.3%). A possible explanation for this trend is the cost and ease of accessibility. Also, our study showed that the use of glucometers was more widespread than newer technologies among the aware patients with diabetes studied (Figure 1).

We found that the main sources of knowledge about the new technologies in managing diabetes were doctors, friends and social media, while the TV played a minor role as a source of knowledge. In the present study, the causes of not using these technologies among the studied patients were high cost, as reported by 53.2% of the respondents (n = 251), non-availability of such technologies (20.3%), difficulty in understanding and use (21.2%), lack of advice from treating doctors (3%), and fear and lack of trust (2.2%). Previous studies [12-14] reported that the most common cause of non-use or discontinuing device use was cost-related. Another study showed reduced usage of mobile applications due to insufficient doctor’s advice on the use of apps for diabetes management [15].

While comparing the use of new technology among the patients with diabetes studied by their demographic and diabetes-related factors we found that the use of new technologies for diabetes management was significantly associated with age < 40 years, type 1 diabetes, and among those patients with HbA1c level between 6.5 and 7.5. There was a higher rate of use among students for all new technologies except for the insulin pump. Also, higher education was significantly associated with the use of CGM and FGM. The one technology that was associated significantly with a duration of diabetes of more than 10 years was the insulin pump. A study by Rafiullah and David [16] in Saudi Arabia showed that the use of health applications was slightly higher (45.91%) among young patients. Also, high educational levels seemed to affect the extent of using health applications.

Regarding mobile health applications, the majority of the patients with diabetes studied used them for blood glucose monitoring (93.4%), physical activity programs (44.3%) and nutritional programs (39.3%), and a few of them used applications for insulin dose determination (3.3%). Similar to our results, Rafiullah and David [16] found that the most common use of mobile health applications was for blood glucose measurement (21.97%) and exercise (18.38%).

Some studies [17-18] noted that greater improvement in blood glucose in patients using mobile platforms or CGM indicated that technologies can enhance diabetes care.

A study by Vaala et al. [19] noted that many different technologies offered professional information about diabetic management that aimed to increase awareness and effectiveness among patients, particularly young patients, such as social media, websites, diabetic applications, text messaging, and pump/glucometer software.

Comparing new technologies to a glucometer, which is the traditional method used in diabetes management, a higher rate of use was found among patients with type 1 (91%) and type 2 (87.7%) DM with ORs of 7.4 and 5.2, respectively, among those patients. Also, we found that the use of glucometers was higher among patients with a duration of diabetes of more than five years and those with higher HbA1c levels.

Patient satisfaction plays an important role in the adherence and success of diabetes management. As this study measured patient satisfaction with modern devices and the traditional device, we found the higher rate of satisfaction for all studied items was related to the patients who use mobile health applications, FGM, and CGM. The lowest rate of satisfaction was found among patients who reported using a glucometer alone (Table 3).

Our findings were supported by a number of studies. A recent systematic review conducted among Saudi patients who use mHealth applications showed a positive effect on their health-related behaviors and outcomes, with a higher rate of satisfaction in comparison to traditional care [14]. A meta-analysis attributed those results to self-management skills such as symptom awareness, monitoring, and management, which were all facilitated by mHealth applications [20]. Regarding FGM, Al Hayek’s study [21], carried out in Saudi Arabia for patients with type 1 diabetes, found that the use of FGM increases the frequency of self-testing, thus helping to reduce the frequency of hypoglycemia and HbA1c level and to
improve the quality of life compared to traditional testing methods. A similar result was reported in another Saudi study for patients with type 2 diabetes [22].

According to the American Diabetes Association (ADA), CGM systems have been increasing in popularity and comfort vs. the standard glucometer [2]. Previous studies [10, 23-25] showed that CGM helps in increasing treatment satisfaction and enhances ease of diabetes care, self-management and psychosocial outcome, and improves glycemic control for patients with type 1 and type 2 diabetes.

In the current study, patients using an insulin pump reported a high rate of satisfaction for only three studied satisfaction items: "I feel generally fine with my diabetes treatment," "Easy and comfortable treatment method," and "I feel confident dealing with my diabetes" (Table 3). Previous studies [6, 26] comparing the insulin pump with traditional treatment methods found an increase in treatment satisfaction with the insulin pump among the studied population.

Our study is the first conducted in Saudi Arabia that discusses multiple new technologies used in the management of DM. However, it has some limitations, as the collection of data was via an online survey, which could have some recall bias and issues of limited sampling.

Conclusions
In conclusion, with the current rapid development of modern technologies in managing diabetes, our findings revealed that the use of these technologies is still limited despite the majority of the participants being aware of them. The main barrier to the non-use of new technologies was primarily their high cost. According to the data, the use of new technologies was more common among certain demographic- and diabetes-related factors, such as the age, type, and duration of diabetes. However, modern technologies have a higher rate of satisfaction in comparison to conventional methods. As the government continues to support patients with diabetes who use traditional methods by distributing glucometers for free to every patient with diabetes in their facilities, it also started providing modern diabetes technologies, such as FGM and insulin pumps, mostly for type 1 patients. Thus, we recommend greater government support and launching financial support programs for patients with diabetes to help them cover the cost of these technologies. We also recommend physicians to encourage their patients in using mobile health applications, as it provides better satisfaction and is considered of a lower cost. This study had some limitations such as being conducted as an online survey; therefore, more research is needed to corroborate these findings in clinical settings and with a larger sample of participants from all of Saudi Arabia’s varied communities to obtain more reliable and focused results.

Appendices
Research questionnaire
This questionnaire is for patients with diabetes in Saudi Arabia. It aims to measure patients’ perspectives of the new technologies that are used to manage diabetes and their satisfaction regarding these technologies.

• Participation is optional.

• Your information will be strictly confidential as soon as you complete the questionnaire.

Demographic information (personal information)
Age: .................

Gender:
1. Female.
2. Male.

Nationality:
1. Saudi.
2. Non-Saudi.

Educational level:
1. Did not receive the traditional education.
2. Primary/intermediate education.
3. High-school education.
4. University and above education.

Occupation:
1. Student.
2. Employed.
3. Unemployed.
4. Student or worker in the health field.

Income Status:
1. High income (>20,000/month).
2. Intermediate income (10,000-20,000/month).
3. Low income (<10,000/month).

Residence:
1. Madinah Al-Munawarah.
2. Makkah Al-Mukaramah.
3. Riyadh.
4. Jeddah.
5. Taif.
6. Dammam.
7. Others.

Health Information
Which type of diabetes do you have?
1. Diabetes mellitus - Type 1
2. Diabetes mellitus - Type 2
3. Gestational diabetes.
4. I do not know.

If you have diabetes mellitus - Type 2, do you use injecting insulin for treatment?
1. Yes.
2. No.

When were you diagnosed with diabetes?
1. Less than a year.
2. 1-5 years.
3. 6-10 years.
4. More than 10 years.

Do you know your hemoglobin A1c test (HbA1c)?
1. Yes
2. No

What is your hemoglobin A1c level?
1. Less than 6.5%.
2. 6.5-7.5%.
3. 7.6-8.5%.
4. More than 8.5%.

**Glucometer**

It is a device used to monitor the level of glucose in the blood using a drop of blood taken by a finger prick, placed on the device strip, read by the meter, and the result of the level of sugar in the blood was taken.

---

Do you use glucometer?
1. Yes.
2. No.

How did you first hear about glucometer?
1. Responsible doctor.
2. TV.
3. Magazine/Newspaper.
4. Social media.
5. A friend/relative/associate.
6. Others: ......

Do you advise/recommend glucometer to a friend or colleague?
1. Definitely not.
2. Probably not.
3. Not sure.
4. Probably.
5. Definitely

How long have you used glucometer?
1. Less than a month.
2. 1 to 6 months.
3. 6 months to a year.

4. More than a year.

Are you still using glucometer until now?

1. Yes.

2. No.

Did you get a glucometer freely from the hospital or health center, or did you buy it at your own expense?

1. Yes, I got it from the hospital or health center.

2. No, I bought it at my own expense.

Do you get the glucometer strips regularly and freely from the hospital or health center, or do you buy them at your own expense?

1. Yes, I got it from the hospital or health center.

2. No, I bought it at my own expense.

**New technologies used in diabetes management**

How well do you know about the new technologies used to manage diabetes, such as [continuous glucose monitoring (CGM), insulin pump, mobile applications, flash glucose monitoring (FGM)]?

1. Never heard of them.

2. I am aware but have never used them.

3. I use them sometimes.

4. I use them regularly.

Why have you not used any of the new technologies? (you can choose more than one option)

1. Cost.

2. Complicated and difficult to use.

3. Unavailable.

4. Others: .....  

If you are willing to use any of these new technologies in the future, which one will be used? (you can choose more than one option)

1. CGM.

2. Insulin pump.

3. Mobile phone applications.

4. FGM.

5. Nothing.

**Continuous glucose monitoring**

It is a device used to measure glucose levels every few minutes using a sensor (needle), which is inserted under the skin (usually in the abdominal wall or arm).
Do you use/have you previously used continuous glucose monitoring?

1. Yes.
2. No.

How did you first hear about CGM?

1. Responsible doctor.
2. TV.
3. Magazine/Newspaper.
4. Social media.
5. A friend/relative/associate.
6. Others: ....

Do you advise/recommend CGM to a friend or colleague?

1. Definitely not.
2. Probably not.
3. Not sure.
4. Probably.
5. Definitely

How long have you used CGM?

1. Less than a month.
2. 1 to 6 months.
3. 6 months to a year.
4. More than a year.

Are you still using CGM until now?

1. Yes.
2. No.

**Flash glucose monitoring**

It is a device used to monitor glucose levels using flash technology in which glucose levels are measured in the interstitial fluid under the skin by placing a sensor on the arm skin, and the readings are obtained by scanning with the specified device or by some mobile devices without the need for a prick.

Do you use/have you previously used FGM?

1. Yes.
2. No.

How did you first hear about FGM?

1. Responsible doctor.
2. TV.
3. Magazine/Newspaper.
4. Social media.
5. A friend/relative/associate.
6. Others: ……

Do you advise/recommend FGM to a friend or colleague?
1. Definitely not.
2. Probably not.
3. Not sure.
4. Probably.
5. Definitely

How long have you used FGM?
5. Less than a month.
6. 1 to 6 months.
7. 6 months to a year.
8. More than a year.

Are you still using FGM until now?
1. Yes.
2. No.

**Insulin pump**

It is a small pumping device that contains an insulin reservoir and a tube for delivering insulin which ends with a thin plastic needle that is inserted under the skin; to deliver certain amounts of insulin found in the reservoir to the body automatically.

Do you use/have you previously used insulin pump?
1. Yes.
2. No.

How did you first hear about insulin pump?
1. Responsible doctor.
2. TV.
3. Magazine/Newspaper.
4. Social media.
5. A friend/relative/associate.
6. Others: ……
Do you advise/recommend insulin pump to a friend or colleague?

1. Definitely not.
2. Probably not.
3. Not sure.
4. Probably.
5. Definitely

How long have you used insulin pump?

1. Less than a month.
2. 1 to 6 months.
3. 6 months to a year.
4. More than a year.

Are you still using insulin pump until now?

1. Yes.
2. No.

**Mobile phone applications**

These are useful applications and programs for patients with diabetes which help them to monitor blood sugar levels, remind them of medication time, or help them to calculate and choose the foods they eat to maintain their calories count, so they can manage their health better.

---

Do you use/have you previously used Mobile phone application for managing diabetes?

1. Yes
2. No

For which purpose do you use mobile phone applications for managing diabetes?

1. Nutrition applications.
2. Physical activity applications.
3. Glucose monitoring applications.
4. Insulin measurement applications.
5. Insulin delivery applications.

How did you first hear about mobile phone applications for managing diabetes?

1. Responsible doctor.
2. TV.
3. Magazine/Newspaper.
4. Social media.
5. A friend/relative/associate.

6. Others: ……

Do you advise/recommend mobile phone applications for managing diabetes to a friend or colleague?

1. Definitely not.
2. Probably not.
3. Not sure.
4. Probably.
5. Definitely

How long have you used mobile phone applications for managing diabetes?

1. Less than a month.
2. 1 to 6 months.
3. 6 months to a year.
4. More than a year.

Are you still using mobile phone applications for managing diabetes until now?

1. Yes.
2. No.

| Items to measure the patient's satisfaction | Strongly agree | Agree | Neutral | Disagree | Strongly disagree |
|-------------------------------------------|----------------|-------|---------|----------|-------------------|
| I am fully satisfied with my diabetes treatment. |                |       |         |          |                   |
| My treatment method is easy and convenient.   |                |       |         |          |                   |
| I feel confident dealing with diabetes.      |                |       |         |          |                   |
| I have no worries about hypoglycemia         |                |       |         |          |                   |
| I have no worries about hyperglycemia        |                |       |         |          |                   |

**TABLE 6: Patient's satisfaction measurement.**
Patient satisfaction was measured for each device.

---

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. Taibah University, College of Medicine Research Ethics Committee (CM-REC) issued approval IORG0008716-IRB00010413. College of Medicine - Research Ethical Committee (CM-REC) of Taibah University has unconditionally approved of the research entitled 'Diabetic patients' perspective about new technologies used in managing diabetes mellitus in Saudi Arabia’ on December 15, 2020. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors declare that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other**
relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Federation ID: IDF Diabetes Atlas. International Diabetes Federation, Brussels; 2021.

2. Drazen B, Areva RD, Bakris G, et al.: Diabetes technology: standards of medical care in diabetes-2022. Diabetes Care. 2022, 45:S97-S112. 10.2337/dc22-S007

3. Beck RW, Riddlesworth TD, Ruedy K, et al.: Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017, 167:565-574. 10.7326/M16-2855

4. Riddlesworth T, Price D, Cohen N, Beck RW: Hypoglycemic event frequency and the effect of continuous glucose monitoring in adults with type 1 diabetes using multiple daily insulin injections. Diabet Ther. 2017, 8:947-951. 10.1007/s13500-017-0281-4

5. Lind M, Polonsky W, Hirsch IB, et al.: Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017, 317:579-587. 10.1001/jama.2016.19976

6. Al Hayek AA, Robert AA, Al Dawish MA, Brabham RB, Goudel H, Al Sabaan FS: Efficacy of insulin pump therapy on diabetes treatment satisfaction and glycemic control among patients with type 1 diabetes mellitus in Saudi Arabia: a prospective study. Diabet Ther. 2015, 6:227-236. 10.1007/s13500-015-0107-1

7. Lelearathina L, Wilmot EG: Flash forward: a review of flash glucose monitoring. Diabet Med. 2018, 35:472-482. 10.1111/dme.13584

8. Fleming GA, Petrie JR, Bengtsson RM, Holl RW, Peters AL, Heinemann L: Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabet Care. 2020, 43:250-260. 10.2337/dci19-0062

9. Harrison S, Stadler M, Ismail K, Amiel S, Hermann-Werner A: Are patients with diabetes mellitus satisfied with technologies used to assist with diabetes management and coping?: A structured review. Diabet Technol Ther. 2014, 16:771-783. 10.1089/dia.2014.0062

10. Hussain T, Akle M, Nagelkerke N, Deeb A: Comparative study on treatment satisfaction and health perception in children and adolescents with type 1 diabetes mellitus on multiple daily injection of insulin, insulin pump and sensor-augmented pump therapy. SAGE Open Med. 2017, 5:2050312117694938. 10.1177/2050312117749598

11. World Health Organization (WHO). Process of translation and adaptation of instruments. (2016). Accessed: 22 Nov 2020: http://www.who.int/substance_abuse/research_tools/translation/en/

12. Tanenbaum ML, Hanes SJ, Miller KM, Naranjo D, Bensen R, Hods DD: Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets. Diabet Care. 2017, 40:181-187. 10.2337/dci16-1536

13. Tanenbaum ML, Adams RN, Hanes SJ, Barley RC, Miller KM, Mulvaney SA, Hods DD: Optimal use of diabetes devices: clinician perspectives on barriers and adherence to device use. J Diabet Sci Technol. 2017, 11:484-492. 10.1175/1932296816688010

14. Vigersky RA: The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus. J Diabet Sci Technol. 2015, 9:320-330. 10.1177/1932296814565561

15. Cerna L, Maresova P: Patients' attitudes to the use of modern technologies in the treatment of diabetes. Patient Prefer Adherence. 2016, 10:1869-1879. 10.2147/PAA.S118040

16. Rafiuullah M, David SK: Health apps usage and preferences among Saudi patients with diabetes: a survey. Int J Clin Pract. 2019, 73:e13545. 10.1111/iipc.13545

17. Offringa R, Sheng T, Parks L, Clements M, Kerr D, Greenfield MS: Digital diabetes management application improves glycemic outcomes in people with type 1 and type 2 diabetes. J Diabet Sci Technol. 2018, 12:701-708. 10.1177/1932296817747291

18. Beck RW, Riddlesworth T, Ruedy K, et al.: Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017, 317:371-378. 10.1001/jama.2016.19975

19. Vaal SE, Hood KK, Laffel LM, Kumah-Crystal YA, Lybarger CK, Mulvaney SA: Use of commonly available technologies for diabetes information and self-management among adolescents with type 1 diabetes and their parents: a web-based survey study. Interact J Med Res. 2015, 4:e24. 10.2196/ijmr.4504

20. Chin-Jung L, Hsiao-Yean C, Yeu-Hui C, Kuan-Chia L, Hui-Chuan H: Effects of mobile health interventions on improving glycemic stability and quality of life in patients with type 1 diabetes: a meta-analysis. Res Nurs Health. 2021, 44:187-200. 10.1002/nur.22094

21. Al Hayek AA, Robert AA, Al Dawish MA: Evaluation of freestyle libre flash glucose monitoring system on glycemic control, health-related quality of life, and fear of hypoglycemia in patients with type 1 diabetes. Cln Med Insights Endocrinol Diabetes. 2017, 11:179951417746957. 10.1177/1179551417746957

22. Al Hayek A, Al Dawish M, El Janmal M: The impact of flash glucose monitoring on markers of glycemic control and patient satisfaction in type 2 diabetes. Cureus. 2021, 13:e16007. 10.7759/cureus.16007

23. Correction to: Diabetes Technology &amp; Therapeutics 2020; 22(5):395-405. Diabetes Technol Ther. 2021, 23:397-398.

24. Covarrubias, E., Uppal, B., Angara, C., et al.: Systematic review of randomized controlled trials evaluating glycemic efficacy and patient satisfaction of intermittent-scanned continuous glucose monitoring in patients with diabetes. Diabet Technol Ther. 2020, 22:537-545. 10.1089/dia.2019.0345

25. Gilbert TR, Noar A, Blaok O, Polonsky WH: Change in hemoglobin A1c and quality of life with real-time continuous glucose monitoring use by people with insulin-treated diabetes in the landmark study. Diabet Technol Ther. 2021, 23:555-539. 10.1089/dia.2020.0666

26. Barnard KD, Brumta M, de Lange M, et al.: High reported treatment satisfaction in people with type 1 diabetes switching to latest generation insulin pump regardless of previous therapy. J Diabet Sci Technol.
